CuraGen Corporation was an early stage biotechnology company that was focused on improving the speed and efficiency of drug development.
Carter Morse & Mathias was engaged during the company’s first year in operation to advise the investors and management and help design a capital formation strategy, assemble a business plan, and to quarterback a capital raising process.
Carter Morse & Mathias assisted in structuring and negotiating the company’s first round of institutional capital in the form of preferred equity capital from a venture capital firm. Curagen subsequently went public with Morgan Stanley and at its height had a market capitalization of $5 billion.
Securities are offered through Carter Capital Corporation, memberFINRA and SIPC.
This information should not be construed as a recommendation, offer to sell, or solicitation of an offer to buy a particular security or investment strategy. The commentary provided is for informational purposes only and should not be relied on for accounting, legal, tax or other professional advice. While the information herein is deemed reliable, CMM cannot guarantee its accuracy, completeness, or suitability for any purpose, and makes no warranties with regard to the results to be obtained from its use.